Antibody-based imaging of a particularly aggressive form of breast cancer is undergoing clinical trials worldwide, but the path from trial to application is being hampered by a major obstacle: safety.
Concerns stem from inefficient tumor targeting, which can result in accumulation in the bone marrow, liver and kidneys of the radioactive material necessary for the imaging. Recent efforts have focused on nanoscale delivery vehicles with immune components, but these vehicles are often still too large (20 nanometers or larger) for renal clearance after imaging.
Researchers now have proposed a novel approach using ultrasmall silica nanoparticles - better known as "Cornell dots" (or C dots). Their team equipped the C dots with antibody fragments. Because the resulting conjugates are smaller than 8 nanometers, these C dots allow for renal clearance while achieving the specificity needed for efficient tumor targeting.They report their discovery in Nature Communications.
Cornell dots and their newer generation - termed "Cornell prime dots," or simply C' dots - have evolved since the group introduced them in 2005 and since, a first clinical trial deemed them safe for humans in 2014. Two years ago, the dots were shown to have the ability not only to detect cancer cells but to be self-therapeutic thereby actually killing them.
This latest research puts C dots back into the role of cancer-finder, but adds a "tumor finder" in the form of an antibody fragment. They used a particular fragment of the Y-shaped antibody, as opposed to the whole molecule, to keep the C' dot within the size threshold for renal clearance.
The target: HER2-positive breast cancer, more aggressive and deadly than HER2-negative cancer, making it an attractive target for new diagnostics and therapies. In the collaboration, MedImmune engineered an antibody fragment specifically to target the HER2 protein and a conjugation site not interfering with its binding activity. The dot itself was synthesized in a way that gave it five distinct functions, all within its ultrasmall size of 6 to 7 nanometers.
Both in vitro and in vivo (mouse) targeting of HER2-positive breast cancer cells were successful, with in vivo tumor uptake of the injected dots as high as 17.2 percent. "The injection circulates through the blood and has to escape the vasculature, has to diffuse through the connective tissue, has to associate with the tumor and then kind of penetrate the tumor body," the author said. "We want 100 percent - everybody wants 100 percent. But when you consider all of the other things that are competing for the vehicle elsewhere in the body, 17 percent is not that small."
http://news.cornell.edu/stories/2018/10/latest-cornell-dot-features-new-cancer-weapon-antibodies
https://www.nature.com/articles/s41467-018-06271-5
Latest News
Ancient viral DNA in the hu…
By newseditor
Posted 26 May
AI to analyze clumping prot…
By newseditor
Posted 26 May
Reversible, non-hormonal ma…
By newseditor
Posted 26 May
Dissection of the schizophr…
By newseditor
Posted 26 May
Protease action on controll…
By newseditor
Posted 25 May
Other Top Stories
New anti-phage defence mechanisms in bacteria
Read more
Inactivated COVID-19 protects macaques from infection
Read more
Statin drugs might boost healthy gut microbes
Read more
Neutralization of Betacoronaviruses by Antibodies
Read more
Stress increases vulnerability to virus
Read more
Protocols
SEMORE: SEgmentation and MO…
By newseditor
Posted 26 May
Spatially resolved lipidomi…
By newseditor
Posted 24 May
Efficient expansion and CRI…
By newseditor
Posted 21 May
Massively parallel in vivo…
By newseditor
Posted 20 May
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Publications
Integrating human endogenou…
By newseditor
Posted 26 May
The thalamic reticular nucl…
By newseditor
Posted 26 May
PMI-controlled mannose meta…
By newseditor
Posted 26 May
Protein-membrane interactio…
By newseditor
Posted 26 May
Toward an interventional sc…
By newseditor
Posted 26 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar